Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
In: Lancet, Jg. 379 (2012-04-21), Heft 9825, S. 1508-1516
Online
academicJournal
Zugriff:
The article presents a study which investigates the effect of gemtuzumab ozogamicin to the improvement of patients with leukemia without causing excessive toxicity. The study uses the randomized open-label phase three analysis in patients aged 50-70 years in haematology centres in France. Results show that the safe delivery of higher cumulative doses is allowed by the use of fractionated lower doses of gemtuzumab ozogamicin.
| Titel: |
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
|
|---|---|
| Autor/in / Beteiligte Person: | Castaigne, Sylvie ; Pautas, Cécile ; Terré, Christine ; Raffoux, Emmanuel ; Bardessoule, Dominique ; Bastie, Jean-Noel ; Legrand, Ollivier ; Thomas, Xavier ; Turlure, Pascal ; Reman, Oumedaly ; Revel, Thierry de ; Gastaud, Lauris ; Gunzburg, Noémie de ; Contentin, Nathalie ; Henry, Estelle ; Marolleau, Jean-Pierre ; Aljijakh, Ahmad ; Rousselot, Philippe ; Fenaux, Pierre ; Preudhomme, Claude |
| Link: | |
| Zeitschrift: | Lancet, Jg. 379 (2012-04-21), Heft 9825, S. 1508-1516 |
| Veröffentlichung: | 2012 |
| Medientyp: | academicJournal |
| ISSN: | 0140-6736 (print) |
| DOI: | 10.1016/S0140-6736(12)60485-1 |
| Schlagwort: |
|
| Sonstiges: |
|